Incidence and predictors of HBsAg loss following addition of pegylated interferon Alfa-2b in chronic hepatitis B patients suppressed by nucleos(t)ide analogues: a multicenter, prospective, cohort study
CHB patients with low HBsAg levels and virologic suppression on NAs can achieve significant HBsAg loss after adding PegIFNα-2b. A two-step strategy based on baseline HBsAg and week-12 HBsAg decline may aid patient selection and treatment optimization.
Authors
- Sujun Zheng
- Dandan Bian
- Ge Shen
- F. Lu
- Jun Lv
- Liaoyun Zhang
- Dongying Xie
- Lanyi Lin
- Bo Feng
- Jing Zhao
- Xiaoyuan Xu
Institutions
- North China Electric Power University (CN)
- Sun Yat-sen University (CN)
- Shanxi Medical University (CN)
- Shanghai Jiao Tong University (CN)
- Peking University (CN)
- Ruijin Hospital (CN)
- Peking University People's Hospital (CN)
- First Hospital of Shanxi Medical University (CN)
- Peking University First Hospital (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
- Beijing YouAn Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Virology Journal
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1186/s12985-026-03086-5
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00